- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Aptamer Group PLC - Agreement with global life sciences leader | - | RNS | ||
| APTAMER GROUP Aktie jetzt für 0€ handeln | |||||
| 30.05. | Aptamer signs second Optimer programme contract with Unilever | 5 | Sharecast | ||
| 30.05. | Aptamer cheers second product development deal with Unilever | 3 | Alliance News | ||
| 30.05. | Aptamer Group PLC - Unilever second Optimer development programme | 5 | RNS | ||
| 15.05. | Aptamer Group Inks New Development Deals, Licensing Agreement | 1 | Contract Pharma | ||
| 15.05. | AIM WINNERS & LOSERS: Aptamer wins deals; DSW beats market view | 2 | Alliance News | ||
| 15.05. | Aptamer Group PLC - Aptamer Announces New Data at ASGCT | - | RNS | ||
| 15.05. | Aptamer Group PLC - Optimer licensing agreements and repeat contracts | - | RNS | ||
| 06.05. | Aptamer Group PLC - Alzheimer's test advanced and royalty agreement | - | RNS | ||
| 30.04. | Aptamer Group PLC - Licensing agreed for Optimer as vaccine adjuvant | - | RNS | ||
| 29.04. | Aptamer Group PLC - Aptamer Presenting at ASGCT Annual Meeting | - | RNS | ||
| 24.04. | Aptamer Group PLC - New Corporate Presentation and Investor Factsheet | - | RNS | ||
| 11.03. | Aptamer Group PLC - Interim Results | 1 | RNS | ||
| 27.02. | Dowgate Group reduces stake in Aptamer Group PLC | 1 | Investing.com | ||
| 27.02. | Aptamer Group PLC - TR-1: Standard form notification of major holdings | - | RNS | ||
| 25.02. | Aptamer Group PLC - Notice of Results and Investor Presentation | 1 | RNS | ||
| 28.01. | Aptamer Group issues shares for director fees | 1 | Investing.com | ||
| 28.01. | Aptamer Group PLC - Issue of Equity in lieu of Director fees | - | RNS | ||
| 28.01. | Aptamer Group PLC - Half Year Trading Update | - | RNS | ||
| 13.01. | Director dealings: Conygar, Aptamer insiders buy shares | 1 | Sharecast |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -6,35 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
| BIONTECH | 90,70 | -0,60 % | Biotech Report: Biontech rutschen ab; Sektor an der Wall Street leichter | (shareribs.com) Frankfurt / New York 23.06.2025 - Biotech-Aktien zeigen sich im deutschen Handel überwiegend leichter. Unter anderem sacken Biontech kräftig ab. Auch an der Wall Street bewegt sich der... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
Das Unternehmen APTAMER GROUP PLC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,002 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APTAMER GROUP PLC finden Sie auf Wallstreet Online.